ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,232.77
0.04%
US Tech 100
22,099.60
0.08%
Dow Jones
44,286.45
-0.27%
Brent Oil
70.025
1.10%
Bitcoin
109,093.81
0.72%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Stoke Therapeutics Inc (STOK) Quote

Stoke Therapeutics Inc

Stoke Therapeutics Inc (STOK)

NASDAQ
12.02
0.33
( 2.82% )
Updated: 13:39:36
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
12.02
( 2.82% )
Bid
12.01
Ask
12.04
Volume
245,324
11.70 Day's Range 12.25
5.35 52 Week Range 16.15
Market Cap
656.255M
Previous Close
11.69
Open
11.73
Last Trade
3
@
12.025
Last Trade Time
13:39:37
Financial Volume
$ 2,944,356
VWAP
12.0019
Average Volume (3m)
684,144
Shares Outstanding
54,596,924
Dividend Yield
-
PE Ratio
-7.33
Earnings Per Share (EPS)
-1.63
Revenue
36.56M
Net Profit
-88.98M

About Stoke Therapeutics Inc

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.stoketherapeutics.com
Headquarters
Dover, Delaware, USA
Founded
-
Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was $11.69. Over the last year, Stoke Therapeutics shares have traded in a share price range of $ 5.35 to $ 16.15.

Stoke Therapeutics currently has 54,596,924 shares outstanding. The market capitalization of Stoke Therapeutics is $638.24 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -7.33.

Ask ADVFN Intelligence (AI)

STOK Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
July 02 2025
STOK (2.82%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
July 01 2025
STOK (2.82%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
June 23 2025
STOK (2.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 04 2025
STOK (2.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 04 2025
STOK (2.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 04 2025
STOK (2.82%)

Form 8-K - Current report
Edgar (US Regulatory)
June 04 2025
STOK (2.82%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.776.8444444444411.2512.2511.1939551211.61783819CS
40.897.9964061096111.1312.2511.1254649111.61298815CS
124.6162.21322537117.4112.257.316841449.96951928CS
262.4825.99580712799.5412.985.357860859.20253889CS
52-1.33-9.9625468164813.3516.155.3567483610.86283141CS
156-2.22-15.589887640414.2422.873.3552326610.72488936CS
260-11.07-47.94283239523.0971.583.3539251614.34465631CS

STOK - Frequently Asked Questions (FAQ)

What is the current Stoke Therapeutics share price?
The current share price of Stoke Therapeutics is $ 12.02
How many Stoke Therapeutics shares are in issue?
Stoke Therapeutics has 54,596,924 shares in issue
What is the market cap of Stoke Therapeutics?
The market capitalisation of Stoke Therapeutics is USD 638.24M
What is the 1 year trading range for Stoke Therapeutics share price?
Stoke Therapeutics has traded in the range of $ 5.35 to $ 16.15 during the past year
What is the PE ratio of Stoke Therapeutics?
The price to earnings ratio of Stoke Therapeutics is -7.33
What is the cash to sales ratio of Stoke Therapeutics?
The cash to sales ratio of Stoke Therapeutics is 17.85
What is the reporting currency for Stoke Therapeutics?
Stoke Therapeutics reports financial results in USD
What is the latest annual turnover for Stoke Therapeutics?
The latest annual turnover of Stoke Therapeutics is USD 36.56M
What is the latest annual profit for Stoke Therapeutics?
The latest annual profit of Stoke Therapeutics is USD -88.98M
What is the registered address of Stoke Therapeutics?
The registered address for Stoke Therapeutics is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Stoke Therapeutics website address?
The website address for Stoke Therapeutics is www.stoketherapeutics.com
Which industry sector does Stoke Therapeutics operate in?
Stoke Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WWWW International Inc
$ 41.095
(16,364.34%)
627.11k
PROKProKidney Corporation
$ 3.99
(557.87%)
275.73M
NDRAENDRA Life Sciences Inc
$ 7.42
(114.66%)
83.22M
BTCSBTCS Inc
$ 5.34
(90.71%)
71.26M
WKHSWorkhorse Group Inc
$ 3.05
(74.29%)
45.58M
PHHPark Ha Biological Technology Company Ltd
$ 4.08
(-90.05%)
1.81M
ABVEAbove Food Ingredients Inc
$ 0.45
(-33.75%)
3.27M
GIBOGIBO Holdings Ltd
$ 0.04295
(-31.17%)
142.25M
BSGMBioSig Technologies Inc
$ 8.28
(-28.31%)
5.85M
BGLBlue Gold Limited
$ 53.7014
(-28.08%)
108.01k
PROKProKidney Corporation
$ 3.99
(557.87%)
275.73M
GVHGlobavend Holdings Ltd
$ 0.0866
(6.13%)
195.68M
ZVSAZyVersa Therapeutics Inc
$ 0.997399
(51.05%)
188.87M
GIBOGIBO Holdings Ltd
$ 0.04295
(-31.17%)
142.25M
RLYBRallybio Holdings LLC
$ 0.4809
(41.27%)
141.66M

STOK Discussion

View Posts
PonkenPlonken PonkenPlonken 7 months ago
I am so STOKED about this company. They were doing this before they all figured out you need RNA science for gene therapy.
See SRPT ARWR deal! another AAV based gene tx seeking RNAI
👍️0
Monksdream Monksdream 10 months ago
FOLD under $15
👍️0
Zardiw Zardiw 1 year ago
$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
TimeFades TimeFades 1 year ago
Choppy day shoulda just stuck with my morning short
👍️0
TimeFades TimeFades 1 year ago
Got bullish again and covered
👍️0
TimeFades TimeFades 1 year ago
Short from 12s
👍️0
Invest-in-America Invest-in-America 1 year ago
STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
👍️0

Your Recent History

NASDAQ
STOK
Stoke Therapeutics
Delayed Upgrade Clock
ADVFN
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads